Tomoo Kobayashi
YOU?
Author Swipe
View article: Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues
Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues Open
Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC) worldwide. Nucleos(t)ide analogues (NAs) are widely used in chronically HBV‐infected patients, but the risk of HCC still remains in NA‐treated p…
View article: Hypozincemia Is Associated With Increased Tyrosine Levels, Low Handgrip Strength, Increased Incidence of <scp>HCC</scp>, and Liver Disease Progression—A Cross‐Sectional Study
Hypozincemia Is Associated With Increased Tyrosine Levels, Low Handgrip Strength, Increased Incidence of <span>HCC</span>, and Liver Disease Progression—A Cross‐Sectional Study Open
Background Serum zinc levels decrease in chronic liver disease (CLD), but their effects on liver reserve function, tyrosine, skeletal muscle mass, handgrip strength (HGS), and hepatocellular carcinoma (HCC) development remain poorly unders…
View article: Comparison of hepatitis B virus genotype B and C patients in Japan in terms of family history and maternal age at birth
Comparison of hepatitis B virus genotype B and C patients in Japan in terms of family history and maternal age at birth Open
Aim Hepatitis B virus of genotypes B (HBV/B) and C (HBV/C) prevails in Japan and patients with HBV/B have been known to be older than those with HBV/C, but the reason has remained unknown. We aimed to clarify the reason by focusing on the …
View article: Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study Open
Backgrounds: Entecavir (ETV) and tenofovir alafenamide fumarate (TAF) have been used widely to treat patients with chronic hepatitis B virus (HBV) infection, but it is still unclear how best to use these drugs. Although some studies compar…
View article: Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study
Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study Open
Patients with a chronic hepatitis B virus (HBV) infection who are treated with nucleos(t)ide analogues (NAs) are still at risk for hepatocellular carcinoma (HCC), and it has been clinically questioned whether patients with a high risk of H…
View article: Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir Open
Nucleos(t)ide analogues (NAs) suppress hepatitis B virus (HBV) replication, but the risk of hepatocellular carcinoma still remains. The presence of detectable HBV DNA in the serum during NA therapies for chronic hepatitis B patients has be…
View article: Switching to tenofovir disoproxil fumarate in entecavir‑treated chronic hepatitis B patients: A pilot randomized controlled study
Switching to tenofovir disoproxil fumarate in entecavir‑treated chronic hepatitis B patients: A pilot randomized controlled study Open
Although hepatitis B surface antigen (HBsAg) removal is considered the goal of chronic hepatitis B treatment, it can rarely be achieved with nucleos(t)ide analogues (NAs). It has been reported that tenofovir disoproxil fumarate (TDF) is su…
View article: Patients with liver carcinogenesis in C type chronic liver disease who achieved sustained virological response with direct acting antiviral (DAA) treatment
Patients with liver carcinogenesis in C type chronic liver disease who achieved sustained virological response with direct acting antiviral (DAA) treatment Open
We examined 1388 patients with chronic liver disease type C without liver cancer history who achieved sustained virological response for 24 weeks or more (SVR24) with direct acting antiviral (DAA) treatment. We assessed the carcinogenic st…
View article: Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment
Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment Open
It is important to determine the genotypes or serotypes of hepatitis C virus (HCV) in patients before treatment with direct-acting antiviral agents (DAAs), because the effects of DAAs differ among genotypes. In Japan, two tests for HCV typ…